Citations

Clear

39 citation(s) found for "Simner, Patricia".

Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group
Hanson, Kimberly E. , Banerjee, Ritu , Doernberg, Sarah B. , Komarow, Lauren , Satlin, Michael J. , Schwager, Nyssa, Simner, Patricia J. , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Abbenante, Erin, Baum, Keri, Souli, Maria , Mocka, Elizabeth, Hopkins, D. E., Giri, Abhigya, Zeng, Lijuan , Greenwood‐Quaintance, Kerryl E. , Booth, Grant, Waller, Jason, Raza, Praneeta , Sund, Zoë, Wickward, Cathy, Dai, Weixiao , Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Patel, Robin , Evans, Scott R , Hanson, Kimberly , Evans, Scott , Tillekeratne, L. Gayani , Group, for the Antibacterial Resistance Leadership, Tsalik, Ephraim L. , Hopkins, Deborah, Dodd, Andrew, Li, Yixuan , Hamasaki, Toshimitsu , Samuel, Tamika

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S314-S320

10.1093/cid/ciad541 | PMID 37843119 Get It

Abstract The advancement of infectious disease diagnostics, along with studies devoted to infections caused by gram-negative and gram-positive bacteria, is a top scientific priority of the Antibacterial Resistance Leadership Group (ARLG). Diagnostic tests for infectious diseases are rapidly evolving and improving. However, the availability of rapid tests designed to determine antibacterial resistance or susceptibility directly in clinical specimens remains limited, especially for gram-negative organisms. Additionally, the clinical impact of many new tests, including an understanding of how best to use them to inform optimal antibiotic prescribing, remains to be defined. This review summarizes the recent work of the ARLG toward addressing these unmet needs in the diagnostics field and describes future directions for clinical research aimed at curbing the threat of antibiotic-resistant bacterial infections.
Reporting of Antimicrobial Resistance from Blood Cultures, an Antibacterial Resistance Leadership Group Survey Summary: Resistance Marker Reporting Practices from Positive Blood Cultures
Simner, Patricia J. , Bard, Jennifer Dien , Doern, Christopher D. , Johnson, J. Kristie , Westblade, Lars F. , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Patel, Robin , Yenokyan, Gayane , Hanson, Kimberly E. , Group, for the Antibacterial Resistance Leadership

Mayo Clinic

Clinical Infectious Diseases | December 15, 2022 | Volume: 76 | Issue: 9 | Pages: 1550-1558

10.1093/cid/ciac952 | PMID 36533704 Get It

Abstract Background We assessed how laboratories use and handle reporting of results of rapid diagnostics performed on positive blood culture broths, with a focus on antimicrobial resistance (AMR) markers. Methods A survey assembled by the Antibacterial Resistance Leadership Group Diagnostics Committee was circulated from December 2020 to May 2021. The survey was sent to local hospitals, shared on the ClinMicroNet and Division C listservs, and included in a College of American Pathologists proficiency testing survey. Results Ninety-six laboratories of various sizes across the United States (95%) and outside of the United States (5%) participated. Of the laboratories that had at least 1 rapid diagnostic in place (94%), significant heterogeneity in methods used and reporting practices was found across community (52%) and academic (40%) laboratories serving hospitals of various sizes. Respondents had implemented 1 to 6 different panels/platforms for a total of 31 permutations. Methods of reporting rapid organism identification and AMR results varied from listing all targets as “detected”/“not detected” (16–22%) without interpretive guidance, to interpreting results (23–42%), or providing therapeutic guidance comments to patient-facing healthcare teams (3–17%). Conclusions Current approaches to reporting molecular AMR test results from positive blood culture vary significantly across clinical laboratories. Providing interpretative comments with therapeutic guidance alongside results reported may assist clinicians who are not well-versed in genetic mechanisms of AMR. However, this is currently not being done in all clinical laboratories. Standardized strategies for AMR gene result reporting are needed.
Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis
Simner, Patricia J. , Cherian, Jerald , Bergman, Yehudit , Beisken, Stephan , Fackler, Joseph , Hopkins, Robert J., Tamma, Pranita D. , Tamma, Pranita D , Bergman, Yehudit , Suh, Gina A. , Lee, Martin W.

Mayo Clinic

JAC-Antimicrobial Resistance | April 14, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/jacamr/dlac046 | PMID 35529052 Get It

Abstract Background Pseudomonas aeruginosa has the ability to exhibit resistance to a broad range of antibiotics, highlighting the importance of identifying alternative or adjunctive treatment options, such as phages. Patients and methods We report the case of a 25-year-old male who experienced an accidental electrocution resulting in exposed calvarium in the left parieto-temporal region, complicated by a difficult-to-treat P. aeruginosa (DTR-P. aeruginosa) infection. Cefiderocol was the sole antibiotic with consistent activity against six bacterial isolates obtained from the infected region over a 38 day period. Results WGS analysis identified a blaGES-1 gene as well as the MDR efflux pumps MexD and MexX in all six of the patient’s ST235 DTR-P. aeruginosa isolates, when compared with the reference genome P. aeruginosa PA01 and a P. aeruginosa ST235 isolate from an unrelated patient. After debridement of infected scalp and bone, the patient received approximately 6 weeks of cefiderocol in conjunction with IV phage Pa14NPøPASA16. Some improvement was observed after the initiation of cefiderocol; however, sustained local site improvement and haemodynamic stability were not achieved until phage was administered. No medication-related toxicities were observed. The patient remains infection free more than 12 months after completion of therapy. Conclusions This report adds to the growing literature that phage therapy may be a safe and effective approach to augment antibiotic therapy for patients infected with drug-resistant pathogens. Furthermore, it highlights the importance of the GES β-lactamase family in contributing to inactivation of a broad range of β-lactam antibiotics in P. aeruginosa, including ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam.
Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status
Peaper, David R. , Rhoads, Daniel D. , Sullivan, Kaede V. , Couturier, Marc Roger , Humphries, Romney M. , Nolte, Frederick S. , Rowlinson, Marie‐Claire , She, Rosemary C. , Simner, Patricia J. , Theel, Elitza S. , Wojewoda, Christina , Nolte, Frederick S , Simner, Patricia J , Theel, Elitza S , Wojewoda, Christina M , Humphries, Romney , Rhoads, Daniel D , Martin, Isabella W.

Mayo Clinic

Journal of Clinical Microbiology | July 14, 2021 | Volume: 59 | Issue: 10 | Pages: No page available

10.1128/jcm.01167-21 | PMID 34260276 Get It

The U.S. Food & Drug Administration (FDA) regulates the marketing of manufacturers’ in vitro diagnostic tests (IVDs), including assays for the detection of SARS-CoV-2.
Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner, Patricia J. , Patel, Robin , Patel, Robin

Mayo Clinic

Journal of Clinical Microbiology | July 30, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.00951-20 | PMID 32727829 Get It

Cefiderocol (formerly S-649266) is a novel siderophore-conjugated cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram-negative bacilli. The siderophore component binds iron and uses active iron transport for drug entry into the bacterial periplasmic space. The cephalosporin moiety is the active antimicrobial component, structurally resembling a hybrid between ceftazidime and cefepime. Like other β-lactam agents, the principal bactericidal activity of cefiderocol occurs via inhibition of bacterial cell wall synthesis by binding of penicillin-binding proteins (PBPs) and inhibiting peptidoglycan synthesis, leading to cell death.
Mycobacteria
Simner, Patricia J. , Woods, Gail L. , Wengenack, Nancy L.

Mayo Clinic

Diagnostic Microbiology of the Immunocompromised Host | February 21, 2020 | Volume: No volume available | Issue: No issue available | Pages: 367-389

10.1128/9781555819040.ch16 Get It

Evaluation of the NG-Test MCR-1 Lateral Flow Assay and EDTA-Colistin Broth Disk Elution Methods To Detect Plasmid-Mediated Colistin Resistance among Gram-Negative Bacterial Isolates
Fenwick, Alexander J. , Bergman, Yehudit , Lewis, Shawna, Yee, Rebecca , Cole, Nicolynn C., Kohner, Peggy C., Ordak, Carly, Green, Daniel A. , Humphries, Romney M. , Simner, Patricia J. , Cole, Nicolynn, Kohner, Peggy, Green, Daniel A , Humphries, Romney , Uhlemann, Anne‐Catrin , Schuetz, Audrey N. , Bergman, Yehudit

Mayo Clinic

Journal of Clinical Microbiology | January 24, 2020 | Volume: 58 | Issue: 4 | Pages: No page available

10.1128/jcm.01823-19 | PMID 31996440 Get It

Plasmid-mediated colistin resistance (PMCR) is a global public health concern, given its ease of transmissibility. The purpose of this study was to evaluate two methods for the detection of PMCR from bacterial colonies: (i) the NG-Test MCR-1 lateral flow immunoassay (LFA; NG Biotech, Guipry, France) and (ii) the EDTA-colistin broth disk elution (EDTA-CBDE) screening test method. These methods were evaluated using a cohort of contemporary, clinical Gram-negative bacillus isolates from 3 U.S. academic medical centers (126 isolates of the Enterobacterales , 50 Pseudomonas aeruginosa isolates, and 50 Acinetobacter species isolates; 1 isolate was mcr positive) and 12 mcr -positive CDC-FDA Antibiotic Resistance (AR) Isolate Bank isolates for which reference broth microdilution colistin susceptibility results were available.
Evaluation of Calcium-Enhanced Media for Colistin Susceptibility Testing by Gradient Agar Diffusion and Broth Microdilution
Green, Daniel A. , Maćešić, Nenad , Lopez, Mabel, Stump, Stephania , Whittier, Susan , Simner, Patricia J. , Humphries, Romney M. , Humphries, Romney , Uhlemann, Anne‐Catrin , Lopez, Mabel, Schuetz, Audrey N.

Mayo Clinic

Journal of Clinical Microbiology | November 20, 2019 | Volume: 58 | Issue: 2 | Pages: No page available

10.1128/jcm.01522-19 | PMID 31748324 Get It

Despite the increasing reliance on polymyxin antibiotics (polymyxin B and colistin) for treatment of multidrug-resistant Gram-negative infections, many clinical laboratories are unable to perform susceptibility testing due to the lack of accurate and reliable methods. Although gradient agar diffusion is commonly performed for other antimicrobials, its use for polymyxins is discouraged due to poor performance characteristics.
Multicenter Evaluation of Colistin Broth Disk Elution and Colistin Agar Test: a Report from the Clinical and Laboratory Standards Institute
Humphries, Romney M. , Green, Daniel A. , Bergman, Yehudit , Lewis, Shawna, Yee, Rebecca , Stump, Stephania , Lopez, Mabel, Maćešić, Nenad , Uhlemann, Anne‐Catrin , Kohner, Peggy C., Cole, Nicolynn C., Simner, Patricia J. , Uhlemann, Anne-Catrin , Kohner, Peggy, Cole, Nicolynn, Humphries, Romney , Schuetz, Audrey N. , Lopez, Mabel, Bergman, Yehudit

Mayo Clinic

Journal of Clinical Microbiology | September 10, 2019 | Volume: 57 | Issue: 11 | Pages: No page available

10.1128/jcm.01269-19 | PMID 31511331 Get It

Susceptibility testing of the polymyxins (colistin and polymyxin B) is challenging for clinical laboratories. The Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Subcommittee evaluated two methods to enable accurate testing of these agents. These methods were a colistin broth disk elution (CBDE) and a colistin agar test (CAT), the latter of which was evaluated using two inoculum volumes, 1 μl (CAT-1) and 10 μl (CAT-10).